Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab vs cyclophosphamide for ANCA-associated vasculitis (AAVTCZ)
jRCT2031190158Recruiting
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of tocilizumab in microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and Pauci-immune glomerulonephritis (PIGN) (2 arms). Primary endpoint: Complete remission at week 24. Started Oct 2018; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
microscopic polyangiitis (MPA)granulomatosis with polyangiitis (GPA)Pauci-immune glomerulonephritis (PIGN)
Beyond the preview
Go deeper on jRCT2031190158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190158.